Last reviewed · How we verify
AADvac1 160 µg
At a glance
| Generic name | AADvac1 160 µg |
|---|---|
| Sponsor | Axon Neuroscience SE |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AADvac1 160 µg CI brief — competitive landscape report
- AADvac1 160 µg updates RSS · CI watch RSS
- Axon Neuroscience SE portfolio CI